The advent of targeted therapies, such as CXCR2 antagonists, TGF-β blockers, metabolic reprogramming agents, and engineered nanoparticles, has opened new clinical avenues for modulating neutrophil behavior to enhance anti-tumor immunity. The gene discussed is CXCR2; the disease is neoplasm.